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Abstract
Background: Long‐term use of anticholinergics, benzodiazepines and related drugs
(or “Z‐drugs”) have been associated with cognitive impairment and dementia.
However, the relationship of these medications with cognitive function and domain‐
specific neuropsychological performance in older adults without dementia, is
unclear.
Methods: 5135 older adults (74.0 ± 8.3 years; 67.4% female) without a diagnosis of
dementia were recruited in Ireland to the Trinity‐Ulster‐Department of Agriculture
(TUDA) study. Detailed cognitive and neuropsychological assessment was con-
ducted using the Mini‐Mental State Examination (MMSE), Frontal Assessment
Battery (FAB) and Repeatable Battery for Assessment of Neuropsychological Status
(RBANS).
Results: A total of 44% (2259 of 5153) used either a potential or definite anti-
cholinergic medication. Overall, 9.7% (n = 500) used a definite anticholinergic
medication. Regular benzodiazepine use was reported by 7% (n = 363), whilst 7.5%
(n = 387) used a “Z‐drug”. Use of definite, but not potential anticholinergic medi-
cation was associated with poorer performance on all three assessments (β: −0.09;
95% CI: −0.14, −0.03, p = 0.002 for MMSE; β: −0.04; 95% CI: −0.06, −0.02;
p < 0.001 for FAB; β: −4.15; 95% CI: −5.64, −2.66; p < 0.001 for RBANS) in addition
to all domains of the RBANS. Regular benzodiazepine use was also associated with
poorer neuropsychological test performance, especially in Immediate Memory (β:
−4.98; 95% CI: −6.81, −3.15; p < 0.001) and Attention (β: −6.81; 95% CI: −8.60,
−5.03; p < 0.001) RBANS domains.
Conclusions: Regular use of definite anticholinergic medications and benzodiaze-
pines, but not potential anticholinergics or “Z‐drugs”, was associated with poorer
overall and domain‐specific neuropsychological performance in older adults.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
© 2021 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
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Key points
� Use of both anticholinergic medication and benzodiazepines have been associated with
dementia in older adults.
� Use of these medications and domain‐specific cognitive performance in those without de-
mentia, is less well‐understood.
� In >5000 older adults, use of these medications was associated with poorer overall and
domain‐specific cognitive performance.
� These findings have important implications for risk vs benefit decisions of prescribing these
medications in older adults.
1 | INTRODUCTION
The use of medications with anticholinergic properties have been
associated with the later development of dementia in older adults.1–5
Medications with such anticholinergic properties, either as an
intended/potent side effect, are used to treat a wide range of uro-
logical, psychiatric and cardiovascular conditions and are used by
significant proportions of older adults.6,7 Several longitudinal studies
have demonstrated a significantly increased risk of incident Mild
Cognitive Impairment (MCI) and dementia in those regularly using
these medications.2,8 Less well explored is the specific relationship
between these medications and detailed cognitive and neuropsy-
chological performance in community‐dwelling older adults, free
from a diagnosis of dementia.
One of the most convincing longitudinal studies on anticholin-
ergic medication use and incident dementia, involving just‐under
300,000 individuals, demonstrated significant associations between
the use of several types of strong anticholinergic drugs (those with an
anticholinergic cognitive burden score of 2 or 3) and the later risk of
dementia.9 This study follows earlier studies that demonstrated an
effect of strong anticholinergic medication use on cognitive impair-
ment and dementia diagnosis, in addition to accelerated cognitive
decline in those with established dementia using anticholinergic
medications.10 Comparatively fewer studies have focused on specific
domains of cognitive function and the studies that do exist have
typically focused on a relatively small number of general cognitive
tests.11,12 The impact of anticholinergic medication use on specific
domains of detailed neuropsychological and cognitive function has
been less well evaluated.
Regular benzodiazepine use has also been linked to an increased
risk of cognitive impairment. Despite recommendations against their
use in older adults, benzodiazepines and related medications (BDZRs:
Bendoziazepine and Related Medications) are commonly used as
anxiolytics, sedatives, hypnotics and anticonvulsants.13 BDZRs
consist of benzodiazepine and non‐benzodiazepine sedative hyp-
notics (also termed “Z‐drugs”). Several published studies have
examined the impact of BDZRs on dementia diagnosis but, whilst a
number of studies support an association, other studies do not.14–17
Some studies examining BDZRs have demonstrated an association
with poorer cognitive function and/or with the rate of cognitive
decline.18,19 Again, the evidence is somewhat limited in the range of
cognitive tests used and studies examining the association between
these medication classes and detailed tests of neuropsychological
function are lacking.
The Trinity‐Ulster‐Department of Agriculture (TUDA) study
enrolled over five‐thousand adults of >60 years, and free from a
diagnosis of dementia, from two separate jurisdictions on the island
of Ireland. The purpose of the current study was to explore the TUDA
data to investigate the relationship of anticholinergic and BDZR
medication use with neuropsychological performance in this cohort,
based on global cognition and detailed assessments of specific
cognitive domains.
2 | METHODS
2.1 | Study setting and background
The current study was embedded within the TUDA study, which
recruited community‐dwelling older people (aged >60 years), free
from a formal diagnosis of dementia, for detailed health and cognitive
assessment from 2008–2012 (ClinicalTrials.gov identifier:
NCT02664584).20–22 Participants were recruited as part of three
predefined cohorts: (i) hypertensive cohort: from general practices in
the Western and Northern Health and Social Care trusts catchment
area in Northern Ireland; (ii) bone cohort: individuals with a diagnosis
of osteopaenia/osteoporosis, from a specialist tertiary referral bone
clinic at St James's Hospital Dublin and; (iii) cognitive cohort: from
general geriatric clinics/day hospital service at St James's Hospital
Dublin. All participants were free from an established diagnosis of
dementia. All participants provided written informed consent and
underwent identical assessment at all recruitment sites by centrally
trained researchers. Ethical approval was granted from the Research
Ethics Committee in St James's Hospital, Dublin, Ireland and the
Office for Research Ethics Committees Northern Ireland (ORECNI;
ref: 08/NIR03/113).
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2.2 | Medication use
Participants were asked to provide a list of current medications and
information about duration of use. Medications were coded using the
Anatomic Therapeutic Classification (ATC) System. For the current
study, we only included medications which were taken daily (not on
an “as needed”/“prn” basis) and had been used continuously for at
least six months at the time of assessment.
In order to characterise anticholinergic medication use, we used
the Anticholinergic Cognitive Burden (ACB) score.23 The ACB score
assigns a score of 1 (potential anticholinergic medication), two or
three (definite evidence of clinically significant anticholinergic effect)
and the total score for each participant was calculated by combining
an arithmetic sum of the potential/definite anticholinergic medica-
tions used. Further, a binary variable for potential and definite anti-
cholinergic medications were used in order to assess the association
of these medication classes individually with cognitive impairment.
Use of benzodiazepines and related drugs (BDZR) was identified
using the ATC codes: N03AE, N05BA, N05CD and N05CF relating to
benzodiazepine drugs and benzodiazepine‐related sedative hypnotics
(“Z‐Drugs”).
2.3 | Covariate assessment
Routine demographic information was collected as part of the study
visit. Body Mass Index (BMI) was assessed in a standardised fashion.
Participants underwent detailed medical interview which in particular
identified a history of cerebrovascular disease (stroke or transient
ischaemic attack), diabetes, hypertension and cardiovascular disease
(ischaemic heart disease, congestive cardiac failure, myocardial
infarction, atrial fibrillation). Participants also underwent detailed
screening for anxiety (using theHospitalAnxiety andDepression Scale:
HADS) and depressive symptoms (Centre for Epidemiological Studies
Depression Scale: CES‐D).24,25 Further, assessment of personal activ-
ities of daily livingwasmade using the Physical Self‐Maintenance Scale
(PSMS). The component of thePSMSconnected to toileting and related
incontinence symptoms was used in order to adjust for potential uri-
nary incontinence, given that urological agents are one of the com-
monest definite anticholinergics prescribed. Finally, self‐identified
visual impairment was extracted in order to control for indication for
ophthalmological anticholinergic medications.
2.4 | Cognitive assessment
The Mini‐Mental State Examination (MMSE) was used as an assess-
ment of general cognitive function in the current study.26 To assess
frontal lobe function/executive function, the Frontal Assessment
Battery (FAB) was used which assesses conceptualization (assessing
similarities), mental flexibility (verbal fluency), motor programming
(‘Luria’ test), resistance to interference (conflicting instructions),
inhibitory control (via a go‐no go paradigm) and environmental
autonomy (prehension behaviour).27 The Repeatable Battery for
Assessment of Neuropsychological Status (RBANS) was used to
measure performance overall and on specific domains including im-
mediate memory (Index I), visual‐spatial (Index II), language (Index
III), attention (Index IV) and delayed memory (Index V), to provide a
comprehensive neuropsychological assessment.28
2.5 | Statistical analysis
All analysis was carried out using STATA v15.0. Descriptive statistics
are provided as means with standard deviations and proportions with
percentages as appropriate. Between group differences were ana-
lysed using ANOVA and chi‐square tests as appropriate. After
examining data for normality (using Q‐q plots and histograms), data
which did not conform to a normal distribution was log‐transformed
prior to analysis.
In order to assess the relationship between anticholinergic
medication/BDZR use and cognitive function, mixed effects linear
regression was used, with study cohort (cognitive, hypertensive,
bone) considered a random effect and cognitive function (MMSE, log
transformed FAB, RBANS) as the dependent variable. Associations
were tested unadjusted in the first instance (model 1) with adjust-
ment made for age, sex, BMI, family history of dementia and
educational attainment in the second model (model 2). Further
adjustment was made for medical comorbidity (diabetes, hyperten-
sion, ischaemic heart disease, myocardial infarction, cerebrovascular
disease, congestive cardiac failure and total number of regular
medications), alcohol use (current) and smoking (current) under
model 3. Finally, model 4 adjusted for screened anxiety/depressive
symptoms, the presence of visual impairment and symptoms of in-
continence (toileting section of the PSMS) in order to further control
for confounding by indication and protopathic bias.
Analyses were performed in the first instance using total ACB
score as the predictor variable. Given that studies have demon-
strated that it may only be definite anticholinergic medications that
are linked to potential adverse cognitive effects, we repeated analysis
estimating effects for definite and potential anticholinergic medica-
tion use separately (with no regular anticholinergic use as the
reference group in both instances). Analysis were then repeated us-
ing both regular benzodiazepine and finally with regular Z‐drug use
as the independent variable of interest.
Sensitivity analyses were conducted in order to further evaluate
observed associations. In the first instance, we excluded individuals
with intermittent use (“as required”/“prn”) of either anticholinergic or
BDZR medication from both the exposure and reference group, in
order to only assess the impact of regular use vs non‐use. Analyses
were also repeated excluding individuals using both anticholinergic
and BDZR medication, in order to avoid potential interactions be-
tween these medication classes and to estimate the effect of each
medication class individually. In order to evaluate the association in
those without cognitive impairment, given that these medications
may be prescribed in some instances for early symptoms of cognitive
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impairment and that established cognitive impairment may bias re-
sults, we used a MMSE score cut‐off of 24, consistent with the
population under study to define potential cognitive impairment.29
This was carried out in order to assess those with MMSE scores
within the normal range.
Finally, in order to further evaluate the association between
definite anticholinergic medication use and cognitive function, we
divided definite anticholinergics into: (i) antipsychotics; (ii) urologicals
and; (iii) antidepressants which accounted for the majority of definite
anticholinergic use in order to examine if any observed effects were
specific to a particular subclass of anticholinergic medication or
represent an overall class effect. Results of mixed‐effects models are
reported as beta coefficients and 95% confidence intervals (CIs). For
all analysis p < 0.05 was considered the threshold for statistical
significance.
3 | RESULTS
3.1 | Study participants and medication usage
In total, of 5186 recruited to TUDA, 5153 participants were
included in the current study (aged 74.0 ± 8.3 years; 67.4% female)
following exclusion of those with missing data for all three cognitive
assessments (n = 33). Use of any anticholinergic medication (po-
tential or definite) was reported by 44.0% (2259/5153) of partici-
pants whilst 9.7% (500/5,153) regularly used a definite
anticholinergic medication. Of those using any anticholinergic
medication, the median ACB score was 2.1–3 A minority, 7.1% (363/
5135) were regular users of a benzodiazepine medication whilst
7.5% (387/5135) regularly used a “Z‐drug”. Baseline characteristics
by medication use are presented in tabular format below (See
Table 1).
The most common definite anticholinergic medications used
were tolterodine (n = 126), amitriptyline (n = 119), solnifenacin
(n = 50), paroxetine (n = 47), olanzapine (n = 33), oxybutynin (n = 32)
and quetiapine (n = 28). The most common benzodiazepines used
were diazepam (n = 104), temazepam (n = 95), alprazolam (n = 63),
bromazepam (n = 34) and lormatazepam (n = 25). In total, 83 (1.6%)
participants used both a definite anticholinergic medication and a
regular benzodiazepine.
3.2 | Anticholinergic use and neuropsychological
performance
Under unadjusted models, increasing ACB score in addition to both
potential and definite anticholinergic medication use was associated
with significantly poorer cognitive performance on the MMSE, FAB
and RBANS in addition to all RBANS indices (Table 2). Associations
for potential anticholinergics were attenuated under all adjusted
models. Associations between both increasing ACB score and definite
anticholinergic use and poorer performance on the MMSE, FAB,
RBANS and all RBANS indices persisted following robust covariate
adjustment (Table 2).
3.3 | Benzodiazepine and related drug use and
neuropsychological performance
Regular benzodiazepine use was associated with significantly poorer
performance on the MMSE, FAB and RBANS. Under robust covariate
adjustment, associations for poorer performance on total MMSE,
FAB, RBANS in addition to RBANS domains I, III, IV and V with
regular benzodiazepine use persisted (Table 2). Associations between
regular Z‐drug use and poorer cognitive performance were seen
under unadjusted models for total RBANS in addition to RBANS
domain II and III. The associations between regular Z‐drug use and
poorer cognitive performance were attenuated on covariate
adjustment.
3.4 | Anticholinergic medication subclass and
cognitive performance
We divided definite anticholinergic use into regular (i) antipsychotic;
(ii) urological and; (iii) antidepressant use. Associations for antipsy-
chotic use and poorer performance on all total cognitive scores and
RBANS indices were observed and persisted following adjustment.
Regular use of urologicals was associated with poorer performance
on the MMSE and RBANS indices I and III after adjustment. Associ-
ations for anticholinergic antidepressant use were somewhat weaker,
with poorer performance on the total RBANS score persisting
following robust covariate adjustment in addition to indices I, II and V
(See Table 3).
3.5 | Sensitivity analysis
Associations for increasing ACB, definite anticholinergic and benzo-
diazepine use and poorer scores on the MMSE, FAB and RBANS
persisted after excluding individuals with intermittent usage of these
medication classes. Associations for benzodiazepine use and poorer
performance on RBANS index I were attenuated whilst all other as-
sociations between ACB, definite anticholinergic usage and benzo-
diazepine use persisted (Table S1).
On excluding those using both anticholinergic and benzodiaz-
epines, associations for total ACB score, definite anticholinergics
and benzodiazepine use and poorer MMSE score were attenuated.
Associations for definite anticholinergic use and poorer perfor-
mance on the FAB persisted. Finally, associations for total ACB
score, definite anticholinergic use and benzodiazepine use per-
sisted on the total RBANS and RBANS index I and RBANS index
IV whilst associations for poorer performance on index II, III and V
were seen for ACB score and definite anticholinergic use only
(Table S2).
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In order to analyse the association of anticholinergic/benzodi-
azepine and related medication usage with poorer cognitive function,
we re‐ran analysis excluding those with a MMSE score < 24. Using
this analysis, associations for ACB score and definite anticholinergics,
but not benzodiazepines persisted for the FAB whilst associations for
ACB score, definite anticholinergic and benzodiazepine persisted for
total RBANS score. Additionally, associations between benzodiaze-
pine use and poorer performance on RBANS domains I and V were
not observed on excluding those with probable cognitive impairment
based on MMSE score (Table S3).
4 | DISCUSSION
In the current study of over 5000 community‐dwelling older adults,
we demonstrated a significant association between the regular use of
strong anticholinergic medications (for the preceding 6 months) and
benzodiazepines and poorer neuropsychological performance. These
effects were observed for strong anticholinergic use across all do-
mains of cognitive function, and for immediate memory and attention
were most pronounced for benzodiazepine use. This is one of the first
studies to characterise in detail the association between use of these
medications and neuropsychological performance in older adults.
In the current study, associations between definite (but not po-
tential) anticholinergic medication use and cognitive function per-
sisted after robust adjustment for a range of clinical covariates. We
controlled for several factors known to influence cognitive perfor-
mance in older adults (including background medical history, de-
mographic and lifestyle factors). Importantly, by having a
comprehensive assessment of mood and anxiety symptoms, we were
able to control for confounding by indication in individuals prescribed
these medications for management of mood/anxiety symptoms.
Furthermore, we were also able to control for the presence of uro-
logical symptoms and other factors which may result in confounding‐
by‐indication. The issue of confounding‐by‐indication is one of the
consistent issues in the literature examining medication use and
cognition, and we were able to control for this by virtue of the
comprehensive medical assessment performed as part of TUDA.
Importantly, our findings for each persisted on excluding those
with concomitant use of benzodiazepine and strong anticholinergic
medications in addition to excluding those with intermittent use. The
results in this regard hint that the associations observed may be due
to long term use of both medication classes independently and not
simply reflective of overall medication burden. Further, we controlled
for the total number of medications in all of our models and it did not
appear that the associations were simply an effect of overall medi-
cation burden. Finally, by excluding individuals with low MMSE
scores, we reduced the potential for bias owing to established
cognitive impairment. It is also notable that to be included in the
current study, participants were required to be free from a pre‐
existing diagnosis of dementia. By excluding those with a MMSE
score below the population‐based cut‐off for normative Irish data, we
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anticholinergic and benzodiazepine use in those with no objective
signs of established cognitive impairment on the MMSE.
In line with preceding studies, the effect sizes observed in the
current study are relatively small. Whilst our findings highlight po-
tential adverse cognitive effects of strong anticholinergic medications
and benzodiazepines, the risk vs benefit of prescribing these medica-
tions in day‐to‐daypractice should be assessedonan individual basis. It
is alsoworth bearing inmind that to date, there is limited evidence that
decreasing anticholinergic burden in high risk individuals may not
improve cognitive function.30 However, it must be noted that many
studies in this regardhave examined this in individualswith established
cognitive impairment with typically short follow‐up period.30 Trials
aimed at reducing overall anticholinergic burden are needed in older
adultswithout established cognitive impairment to examine the impact
of discontinuation on cognitive and neuropsychological performance.
Not least, our findings would encourage prescribers to consider less‐
anticholinergic alternatives where available (for instance with anti-
depressant medications). Further, the other potential effects of med-
ications in older adults must be taken into account. For instance,
benzodiazepines and Z‐drugs have been associatedwith increased risk
of both falls and delirium, which may be greatest in those with estab-
lished cognitive impairment.31
A notable strength of the current study is the large sample size of
community‐dwelling older adults and the detailed cognitive and
neuropsychological assessments used. An important limitation how-
ever is its cross‐sectional design which precludes inference about
causality. Further longitudinal studies will be required to replicate
and further characterise the specific findings in relation to medica-
tion use and neuropsychological performance in older adults. Like
any study examining the links between medication use and cognition,
we are also unable to exclude confounding by indication/protopathic
bias. Whilst we were able to perform a detailed assessment of
screened anxiety and depressive symptoms in addition to other
important confounders, it is important to reflect that anticholinergic/
benzodiazepines may be used for prodromal symptoms of cognitive
impairment/dementia such as anxiety and sleep disturbance.
5 | CONCLUSIONS AND IMPLICATIONS
In conclusion, we demonstrated an association between strong
anticholinergic medication/benzodiazepine use and cognitive/neuro-
psychological performance in older adults free from a diagnosis of
dementia. Further longitudinal studies will be required to establish
the longitudinal effects of anticholinergic medications and benzodi-
azepine use on specific domains of neuropsychological performance,
in order to identify potential targets for the promotion of brain
health in older adults at risk of cognitive impairment.
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